The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models
Clara Lemos(Bayer (Germany)), Bernard Haendler(Bayer (Germany))
Cited by 42
Related Papers
Dual targeting of the androgen receptor and <scp>PI3K</scp> / <scp>AKT</scp> / <scp>mTOR</scp> pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis
|Molecular Oncology|2024|20